Dow Up0.36% Nasdaq Up0.12%

Oxygen Biotherapeutics, Inc. (OXBT)

4.16 0.05(1.19%) Aug 21, 4:00PM EDT
ProfileGet Profile for:
Oxygen Biotherapeutics, Inc.
ONE Copley Parkway
Suite 490
Morrisville, NC 27560
United States - Map
Phone: 919-855-2100
Fax: 919-855-2133

Index Membership:N/A
Full Time Employees:14

Business Summary 

Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company, focused on the development and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company also develops Oxycyte, a systemic perfluorocarbon product for use as oxygen carrier in the situations of acute ischemia; and a range of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. Its Oxycyte is under Phase II-b clinical trials for the treatment of traumatic brain injury. In addition, the company offers Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. It sells Dermacyte through distribution agreements, on-line retailers, and direct sales to physician and medical spa facilities. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Oxygen Biotherapeutics, Inc.

Key Executives 
Mr. John P. Kelley MBA,
Chief Exec. Officer and Director
Mr. Michael B. Jebsen CPA, 43
Chief Financial Officer, Principal Accounting Officer and Treasurer
Ms. Ellen T. Corliss ,
Sr. VP of Corp. Communications & Investor Relations
Ms. Nancy J. M. Hecox ,
Sr. VP of Legal Affairs, Gen. Counsel and Corp. Sec.
Maria Isabel Tomargo ,
Assistant VP of Marketing & Sales
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders